GlobalRPh Renal Dosing Masterv7.4
Renal Dosing Master: fast drug lookup
Source review / handoff

Linagliptin - single agent (Tradjenta)

One or two intact local summaries. No averaged regimen, patient-specific dose or automatic source preference.

Selecting here opens the current stored cards. The pinned link below records their fingerprints. Do not enter patient information in links or searches.

Share or print this source review

1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.

Copy is optional; the link can be selected and copied manually. No patient data or dose decision is collected.

Clinical context remains essential

Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.

Check source scope before reading a dose

Tradjenta - labeled renal guidance

Product / population
Linagliptin (Tradjenta), oral tablet
Renal method
Renal impairment categories as defined by the cited product label
Source revision
DailyMed SPL version 12, posted Sep 08, 2025
Retrieved
2026-11-07
Local review status
Selected renal passages reviewed; independent clinician adjudication pending.

Documented differences and cautions on this drug

All record notes are retained here, including notes about sources not selected in this review.

Tradjenta - product and source limitations

Apply this finding to the single-ingredient product. Fixed combinations can have different renal restrictions.

What to reconcile: Apply only to the stated formulation, indication and renal population.

Selected renal passages reviewed; independent clinician adjudication pending.

Open this note and its source references
Official

Tradjenta - labeled renal guidance

Open original reference

DailyMed / product prescribing information · Linagliptin (Tradjenta), oral tablet

Renal method: Renal impairment categories as defined by the cited product label
Source date: DailyMed SPL version 12, posted Sep 08, 2025
Retrieved: 2026-11-07

Qualified no-adjustment statement. Apply only to the population, product and renal range described in this source.

Selected renal passages reviewed; independent clinician adjudication pending.

Renal guidance: 8.6 Renal Impairment

Renal impairment does not require a change to the linagliptin dose. Apply this finding to the single-ingredient product. Fixed combinations can have different renal restrictions.

RDM74-tradjenta-official-1 · Source locator: Renal guidance: 8.6 Renal Impairment

Source identity and provenance
Source family
product_label
Source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dfe327e8-f6ab-41e5-bdef-d520118cd83a
Retrieved
2026-11-07
Renal-function method
Renal impairment categories as defined by the cited product label
Source date/version
DailyMed SPL version 12, posted Sep 08, 2025
Hash meaning
SHA-256 of the local selected-source summary
Local summary SHA-256
1d265e8544bb6eafe2f8bf617e92c253c90d1f6590097838658efb1989eb235a

Document the clinical decision separately

This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.

GlobalRPh Renal Dosing Master v7.4. Review the retrieval and revision dates attached to each source. Selecting a reference does not imply clinical verification.

Pinned reference: https://globalrph.com/blogCalcs/renal-dosing-master/compare.php?id=linagliptin&s1=RDM74-tradjenta-official&h1=ddf2d097e7c13fba510bc6d443a2985743056660ae610668c291fbf11a687041

Top